Sales rise at CF firm Vertex Ireland

Irish company fulfils all EU-wide sales and now sells a suite of cystic fibrosis (CF) drugs that includes Kalydeco and Orkambi across the EU

The Irish based unit accounted for 23.4pc of global sales.

Sales of the groundbreaking cystic fibrosis drug, Kaftrio was the main driver behind Vertex Pharmaceutical’s revenues surging to $2.3bn (€2.07bn) last year.

New accounts show revenues at the Dublin-registered Vertex Pharmaceuticals (Ireland) Ltd last year increased by 18% from $1.95bn (€1.75bn) to $2.3bn.